IN2014CN02688A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02688A IN2014CN02688A IN2688CHN2014A IN2014CN02688A IN 2014CN02688 A IN2014CN02688 A IN 2014CN02688A IN 2688CHN2014 A IN2688CHN2014 A IN 2688CHN2014A IN 2014CN02688 A IN2014CN02688 A IN 2014CN02688A
- Authority
- IN
- India
- Prior art keywords
- intestinal
- drug
- drug conjugate
- diseases
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535661P | 2011-09-16 | 2011-09-16 | |
US201261675966P | 2012-07-26 | 2012-07-26 | |
PCT/US2012/055549 WO2013040441A1 (en) | 2011-09-16 | 2012-09-14 | Plant steroids and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN02688A true IN2014CN02688A (de) | 2015-07-03 |
Family
ID=47883793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2688CHN2014 IN2014CN02688A (de) | 2011-09-16 | 2012-09-14 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10086082B2 (de) |
EP (1) | EP2755660B1 (de) |
JP (2) | JP6035338B2 (de) |
KR (1) | KR20140093661A (de) |
CN (2) | CN109384825A (de) |
AU (1) | AU2012308332A1 (de) |
BR (1) | BR112014006222A2 (de) |
CA (1) | CA2848979C (de) |
EA (1) | EA201490637A1 (de) |
HK (1) | HK1200358A1 (de) |
IL (1) | IL231541A0 (de) |
IN (1) | IN2014CN02688A (de) |
MX (1) | MX2014003260A (de) |
SG (1) | SG11201400652UA (de) |
WO (1) | WO2013040441A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105025929A (zh) * | 2013-03-08 | 2015-11-04 | 阿勒根公司 | 环孢菌素a-类固醇缀合物 |
SG11201507244TA (en) | 2013-03-08 | 2015-10-29 | Allergan Inc | Antibiotic conjugates directly linked with steroid drugs |
US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
CA3050001A1 (en) * | 2017-01-13 | 2018-07-19 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
KR102139678B1 (ko) * | 2017-11-24 | 2020-07-31 | 전북대학교 산학협력단 | N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물 |
CN110051674A (zh) * | 2018-07-26 | 2019-07-26 | 中国人民解放军空军军医大学第一附属医院 | 豆甾醇在制备治疗胃癌的药物中的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2946600A (en) * | 1999-03-04 | 2000-09-21 | Eugene Science Inc. | Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same |
CN1237071C (zh) * | 1999-06-23 | 2006-01-18 | 福布斯医药技术股份有限公司 | 植物甾醇或植物甾烷醇的抗坏血酸衍生物及其组合物、食品和用途 |
WO2002072035A2 (en) * | 2001-03-14 | 2002-09-19 | Lipogenics, Inc. | Novel anti-inflammatory compositions and methods of use |
CN1531436A (zh) | 2001-05-09 | 2004-09-22 | (株)美大富历寿 | 用于增强粘膜吸收的两亲肝素衍生物制剂 |
SE0103765D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | New use |
US20040236125A1 (en) * | 2002-09-25 | 2004-11-25 | Forbes Medi-Tech Inc. | Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation |
WO2004095926A2 (en) * | 2003-04-28 | 2004-11-11 | Monsanto Technology, Llc | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield |
US20050234025A1 (en) * | 2004-04-20 | 2005-10-20 | Forbes Medi-Tech Inc. | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof |
US20070065359A1 (en) * | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
US8809514B2 (en) * | 2006-09-22 | 2014-08-19 | Ge Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference |
EP2088865B1 (de) * | 2006-11-06 | 2015-10-21 | Jina Pharmaceuticals Inc. | Guggulphospholipid-verfahren und zusammensetzungen |
US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
RU2012138047A (ru) | 2010-03-02 | 2014-04-10 | Имадженетикс, Инк. | Композиции, содержащие миристиновую кислоту, и их применения |
-
2012
- 2012-09-14 IN IN2688CHN2014 patent/IN2014CN02688A/en unknown
- 2012-09-14 KR KR1020147009670A patent/KR20140093661A/ko not_active Application Discontinuation
- 2012-09-14 BR BR112014006222A patent/BR112014006222A2/pt active Search and Examination
- 2012-09-14 SG SG11201400652UA patent/SG11201400652UA/en unknown
- 2012-09-14 US US14/345,028 patent/US10086082B2/en not_active Expired - Fee Related
- 2012-09-14 JP JP2014530888A patent/JP6035338B2/ja not_active Expired - Fee Related
- 2012-09-14 CA CA2848979A patent/CA2848979C/en not_active Expired - Fee Related
- 2012-09-14 AU AU2012308332A patent/AU2012308332A1/en not_active Abandoned
- 2012-09-14 CN CN201811306193.8A patent/CN109384825A/zh active Pending
- 2012-09-14 EP EP12832645.1A patent/EP2755660B1/de active Active
- 2012-09-14 CN CN201280056467.7A patent/CN103987390A/zh active Pending
- 2012-09-14 EA EA201490637A patent/EA201490637A1/ru unknown
- 2012-09-14 WO PCT/US2012/055549 patent/WO2013040441A1/en active Application Filing
- 2012-09-14 MX MX2014003260A patent/MX2014003260A/es not_active Application Discontinuation
-
2014
- 2014-03-16 IL IL231541A patent/IL231541A0/en unknown
-
2015
- 2015-01-30 HK HK15101045.6A patent/HK1200358A1/xx unknown
-
2016
- 2016-10-31 JP JP2016212948A patent/JP2017019871A/ja active Pending
-
2018
- 2018-08-29 US US16/116,713 patent/US20190083632A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2755660A4 (de) | 2015-03-18 |
CA2848979A1 (en) | 2013-03-21 |
US20190083632A1 (en) | 2019-03-21 |
CN109384825A (zh) | 2019-02-26 |
JP6035338B2 (ja) | 2016-11-30 |
EA201490637A1 (ru) | 2014-11-28 |
BR112014006222A2 (pt) | 2017-04-11 |
US20150141390A1 (en) | 2015-05-21 |
US10086082B2 (en) | 2018-10-02 |
WO2013040441A1 (en) | 2013-03-21 |
EP2755660B1 (de) | 2019-11-06 |
AU2012308332A1 (en) | 2014-04-10 |
SG11201400652UA (en) | 2014-09-26 |
JP2014526515A (ja) | 2014-10-06 |
CN103987390A (zh) | 2014-08-13 |
EP2755660A1 (de) | 2014-07-23 |
KR20140093661A (ko) | 2014-07-28 |
CA2848979C (en) | 2019-11-05 |
MX2014003260A (es) | 2014-09-08 |
HK1200358A1 (en) | 2015-08-07 |
JP2017019871A (ja) | 2017-01-26 |
IL231541A0 (en) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN02688A (de) | ||
PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
TN2018000094A1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX346439B (es) | Métodos y medios para modificar un genoma vegetal. | |
MY177912A (en) | Vegf neutralizing prodrugs for the treatment of ocular conditions | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
NZ700399A (en) | Boronic acid conjugates of oligonucleotide analogues | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
WO2010085665A3 (en) | Targeted delivery system | |
GB2497453B8 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
EP3377622A4 (de) | Gezielte abgabe von in pflanzenzellen bioverkapselten therapeutischen proteinen an bestimmte zelltypen zur behandlung von krankheiten | |
GB201022049D0 (en) | Methods | |
WO2010117727A3 (en) | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions | |
EP2564849A4 (de) | Prophylaktikum oder therapeutikum für erkrankungen im zusammenhang mit schmerzen im harntrakt | |
MX352788B (es) | La mirra en forma de dosificación vaginal para su uso en el tratamiento de la atrofia vaginal como síntoma menopáusico. | |
MX350868B (es) | Medicamentos y metodos para tratar cancer. | |
UA55818U (ru) | Способ лечения хронических заболеваний роговицы | |
UA100661U (uk) | Спосіб підвищення ефективності лікування хворих на хронічний некаменевий холецистит на тлі метаболічного синдрому |